Close X
Get more out of
by joining the site for free
Free 17-point plan to great health
Twice weekly e-news bulletins
Access to our News, Forums and Blogs
Sign up for free and claim your
17-point plan to great health
Free 17-point plan to great health

Twice weekly e-news bulletins

Access to our News, Forums and Blogs

If you want to read our in-depth research articles or
have our amazing magazine delivered to your home
each month, then you have to pay.

Click here if you're interested
Helping you make better health choices

What Doctors Don't Tell You

In shops now or delivered to your home from only £4.25 an issue!

September 2020 (Vol. 5 Issue 6)

Drugs for arthritis and cancer

About the author: 

Drugs for arthritis and cancer image

Q Have you any information on the new breast cancer drug Femara? I have heard that it is better than tamoxifen

Q Have you any information on the new breast cancer drug Femara? I have heard that it is better than tamoxifen. - E.P., Glasgow

A Femara is the trade name for a new drug called letrozole, manufactured by Novartis. It got its licence in the USA nearly two years ago as a 'first-line drug' for postmenopausal women with breast cancer.

For the last 15 years, tamoxifen, the earlier drug from AstraZeneca, has been the 'treatment of choice' for breast cancer. However, when actually put to the test in clinical trials, the drug has been found to be anything but a choice treatment - mainly due to a combination of poor performance and serious side-effects. Recently, a large study on more than 7000 women concluded that 'the overall risk-to-benefit ratio for the use of tamoxifen in breast cancer prevention is still unclear' (Lancet, 2002; 360: 817-24).

Now, just when the patent rights on tamoxifen are expiring, along comes a new type of drug called an aromatase inhibitor. Unlike tamoxifen, which is an oestrogen-blocker, the new compound stops the action of aromatase, an enzyme involved in oestrogen production. So, although different, the new drug is basically doing the same thing. Three companies have developed their own versions of it: AstraZeneca's is called Arimidex, harmacia offers Aromasin and Novartis has Femara.

It's in the companies' interests to show that the new compound works better than tamoxifen - and sure enough, clinical trials 'supported by' the drug manufacturers have come up with the goods. Arimidex, for example, has been found to be '17 per cent better' than tamoxifen; Pharmacia is a bit behind on their Aromasin trials, but three separate studies have already been concluded on Femara.

The largest one to date was done on more than 900 women with breast cancer. They were randomly split into two groups: one that was given 20 mg of tamoxifen; the other took 2.5 mg of Femara per day.

Judging by the headline results, you would think that the world was witnessing a major breakthrough. Femara was reported to be 'significantly superior' to tamoxifen, with 30 per cent improvements being quoted.

The small print of the study, however, gives a rather different picture. The major advantage of Femara seems to be that it delays 'treatment failure' by less than three months, in other words, it has a marginal effect on arresting the progress of the disease. Furthermore, the doctors admit they found 'no significant difference . . . in the duration of overall clinical benefit'. They also acknowledge that it is too early to tell whether the new drug will have any effect on actual survival times (J Clin Oncol, 2001; 19: 10).

What about side-effects? Reducing these is often one of the primary aims of a drug company when developing an improved version of an old drug. But if that's what Novartis was hoping for with Femara, they must be disappointed. Its side-effect profile is almost identical to tamoxifen's: bone pain, back pain, nausea, joint pain, fatigue and thinning hair are just as frequent with Femara - and those are merely the immediate effects. What the long-term side-effects might be is impossible to assess at present. It took years before tamoxifen was discovered to cause uterine cancer, blood clots and severe gynaecological problems.

One straw in the wind with Femara is thrombophlebitis (vein inflammation with blood clots), a side-effect that is described as 'common' even by the manufacturers themselves (Novartis document, July 2001). And blood clots were one of the major causes of death with tamoxifen.

Another straw is that Femara patients are now talking to each other on the Internet and comparing their symptoms. A few are beginning to complain of 'severe pain below the waist'. One woman finds the pain unbearable, but says forlornly: 'The doctor makes me feel like if I stop taking the drug, I might as well sign my death warrant.'

Sadly, according to the latest evidence, her doctor is wrong.

The eu: do practitioners need to do more? image

The eu: do practitioners need to do more?

Breast-conserving surgery is best for cancer image

Breast-conserving surgery is best for cancer

You may also be interested in...

Support WDDTY

Help support us to hold the drugs companies, governments and the medical establishment accountable for what they do.


Latest Tweet


Since 1989, WDDTY has provided thousands of resources on how to beat asthma, arthritis, depression and many other chronic conditions..

Start by looking in our fully searchable database, active and friendly community forums and the latest health news.

Positive SSL Wildcard

Facebook Twitter

© 2010 - 2020 WDDTY Publishing Ltd.
All Rights Reserved